Discovery and Differential Processing of HLA Class II-Restricted Minor Histocompatibility Antigen LB-PIP4K2A-1S and Its Allelic Variant by Asparagine Endopeptidase.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2020
Historique:
received: 22 11 2019
accepted: 17 02 2020
entrez: 29 3 2020
pubmed: 29 3 2020
medline: 24 3 2021
Statut: epublish

Résumé

Minor histocompatibility antigens are the main targets of donor-derived T-cells after allogeneic stem cell transplantation. Identification of these antigens and understanding their biology are a key requisite for more insight into how graft vs. leukemia effect and graft vs. host disease could be separated. We here identified four new HLA class II-restricted minor histocompatibility antigens using whole genome association scanning. For one of the new antigens, i.e., LB-PIP4K2A-1S, we measured strong T-cell recognition of the donor variant PIP4K2A-1N when pulsed as exogenous peptide, while the endogenously expressed variant in donor EBV-B cells was not recognized. We showed that lack of T-cell recognition was caused by intracellular cleavage by a protease named asparagine endopeptidase (AEP). Furthermore, microarray gene expression analysis showed that PIP4K2A and AEP are both ubiquitously expressed in a wide variety of healthy tissues, but that expression levels of AEP were lower in primary acute myeloid leukemia (AML). In line with that, we confirmed low activity of AEP in AML cells and demonstrated that HLA-DRB1

Identifiants

pubmed: 32218783
doi: 10.3389/fimmu.2020.00381
pmc: PMC7078166
doi:

Substances chimiques

Histocompatibility Antigens Class II 0
Minor Histocompatibility Antigens 0
PIP4K2A protein, human EC 2.7.1.-
Phosphotransferases (Alcohol Group Acceptor) EC 2.7.1.-
Cysteine Endopeptidases EC 3.4.22.-
asparaginylendopeptidase EC 3.4.22.34

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

381

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom

Informations de copyright

Copyright © 2020 Kremer, Bausenwein, Lurvink, Kremer, Rutten, van Bergen, Kretschmann, van der Meijden, Honders, Mazzeo, Watts, Mackensen, Falkenburg and Griffioen.

Références

J Immunol. 2001 Sep 15;167(6):3223-30
pubmed: 11544309
Science. 1998 Feb 13;279(5353):1054-7
pubmed: 9461441
Haematologica. 2012 Aug;97(8):1196-204
pubmed: 22419570
Front Immunol. 2016 Mar 15;7:100
pubmed: 27014279
J Clin Invest. 2005 Dec;115(12):3506-16
pubmed: 16322791
Blood. 2007 May 1;109(9):4089-96
pubmed: 17234742
Clin Cancer Res. 2016 Aug 15;22(16):4185-96
pubmed: 26964570
Blood. 2006 Jun 15;107(12):4954-60
pubmed: 16497972
N Engl J Med. 2006 Apr 27;354(17):1813-26
pubmed: 16641398
J Biol Chem. 2005 May 6;280(18):18498-503
pubmed: 15749706
Exp Hematol. 2003 Sep;31(9):743-51
pubmed: 12962719
Cell. 2002 Oct 4;111(1):51-62
pubmed: 12372300
J Clin Invest. 2017 Feb 1;127(2):517-529
pubmed: 28067665
J Exp Med. 2001 Jan 15;193(2):195-206
pubmed: 11148223
Front Immunol. 2018 Jul 30;9:1774
pubmed: 30105035
Blood. 2003 Jul 15;102(2):621-9
pubmed: 12663445
J Exp Med. 2003 May 19;197(10):1279-89
pubmed: 12743171
Haematologica. 2008 Oct;93(10):1535-43
pubmed: 18768532
Nat Immunol. 2002 Feb;3(2):169-74
pubmed: 11812994
J Exp Med. 2008 Nov 24;205(12):2863-72
pubmed: 19001137
Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2742-7
pubmed: 12601144
Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3837-42
pubmed: 18316730
Immunity. 2018 Aug 21;49(2):247-263.e7
pubmed: 30054205
Front Immunol. 2018 Dec 18;9:3016
pubmed: 30619360
Blood. 2007 Aug 1;110(3):1055-63
pubmed: 17409267
Clin Cancer Res. 2009 Dec 1;15(23):7137-43
pubmed: 19934307
Blood. 1995 Sep 1;86(5):2041-50
pubmed: 7655033
Cancer Res. 2010 Nov 15;70(22):9073-83
pubmed: 21062987
Cancer Immunol Res. 2019 May;7(5):797-804
pubmed: 30890530
Am J Hum Genet. 2007 Sep;81(3):559-75
pubmed: 17701901
Haematologica. 2014 Dec;99(12):1854-9
pubmed: 25150256
Blood. 2009 Oct 22;114(17):3684-92
pubmed: 19706888
Blood. 2006 May 1;107(9):3779-86
pubmed: 16391015
PLoS One. 2016 May 12;11(5):e0155165
pubmed: 27171398
J Pept Res. 2004 May;63(5):426-36
pubmed: 15140160

Auteurs

Anita N Kremer (AN)

Department of Internal Medicine 5, Hematology/Oncology, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany.

Judith Bausenwein (J)

Department of Internal Medicine 5, Hematology/Oncology, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany.

Ellie Lurvink (E)

Department of Hematology, Leiden University Medical Center, Leiden, Netherlands.

Andreas E Kremer (AE)

Department of Internal Medicine 1, Gastroenterology, Pneumology and Endocrinology, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany.

Caroline E Rutten (CE)

Department of Hematology, Leiden University Medical Center, Leiden, Netherlands.

Cornelis A M van Bergen (CAM)

Department of Hematology, Leiden University Medical Center, Leiden, Netherlands.

Sascha Kretschmann (S)

Department of Internal Medicine 5, Hematology/Oncology, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany.

Edith van der Meijden (E)

Department of Internal Medicine 5, Hematology/Oncology, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany.

Maria W Honders (MW)

Department of Hematology, Leiden University Medical Center, Leiden, Netherlands.

Daniela Mazzeo (D)

Division of Cell Signaling & Immunology, School of Life Sciences, University of Dundee, Dundee, United Kingdom.

Colin Watts (C)

Division of Cell Signaling & Immunology, School of Life Sciences, University of Dundee, Dundee, United Kingdom.

Andreas Mackensen (A)

Department of Internal Medicine 5, Hematology/Oncology, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany.

J H Frederik Falkenburg (JHF)

Department of Hematology, Leiden University Medical Center, Leiden, Netherlands.

Marieke Griffioen (M)

Department of Hematology, Leiden University Medical Center, Leiden, Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH